Oculis has completed the final patient visits in both Phase 3 DIAMOND trials of OCS-01, a high-concentration dexamethasone eye drop formulated with OPTIREACH technology for diabetic macular edema. Topline results from the 52-week, two-trial program encompassing more than 800 patients are expected in June 2026, with a potential U.S. filing targeted for the fourth quarter of 2026. If positive, OCS-01 could become the first non-invasive topical therapy for DME, a condition that remains a leading cause of vision loss in working-age adults.
The strategic question is whether a topical steroid that reaches the posterior segment can reset an injection-dominated market and expand treatment to patients who currently delay or avoid care. The DME market has long been defined by office-based intravitreal injections under the medical benefit, supported by strong anti-VEGF brands and steroid implants. A pharmacy-dispensed eye drop, if sufficiently efficacious and safe, would shift clinical workflow, payer management, and patient behavior in ways that ripple far beyond retina clinics.
The need is substantial. Of roughly 1.8 million diagnosed DME patients in the U.S., an estimated one million remain untreated or underserved, and real-world data indicate that about 60% of newly diagnosed patients are untreated a year after diagnosis. Even among treated patients, inadequate response rates to standard-of-care injections are reported around 40%, highlighting DME’s multifactorial biology where inflammation is a meaningful driver. A topical option could be positioned for earlier intervention in milder disease or layered as adjunct therapy for suboptimal responders, potentially broadening the market beyond today’s $3 billion U.S. footprint by capturing patients who never enter or persist in injection-based care.
Execution details will matter. DIAMOND evaluates change in BCVA ETDRS letters at Week 52 as the primary endpoint, with ≥15-letter gains and central subfield thickness reduction as key secondaries. The regimen—six times daily induction for six weeks, then three times daily maintenance through a year—trades clinic-visit burden for adherence risk. Medical Affairs teams will need to define which patients can realistically maintain dosing and how best to monitor steroid-related adverse events such as intraocular pressure increases and cataract in routine practice. For HCPs, especially retina specialists, clear guidance on co-management with optometrists and endocrinologists, titration strategies, and detection of steroid responders will be essential.
Commercial models could be upended. A topical chronic therapy would likely sit under the pharmacy benefit, inviting step therapy constructs and prior authorization criteria that test whether payers accept earlier use without prior anti-VEGF failure. If OCS-01 demonstrates meaningful vision gains and edema reduction, it could be an adjunct that reduces injection frequency, but the lack of active-comparator arms means payers will scrutinize magnitude and durability versus standard-of-care using indirect comparisons and real-world evidence. Health economic narratives should quantify avoided procedure visits and improved persistence, not just drug costs. Access strategy must also account for buy-and-bill revenue dynamics that currently align retina clinics to injections.
Beyond one asset, validation of OPTIREACH as a posterior-segment delivery platform would be strategically significant. Non-invasive retinal delivery has been an elusive goal; a credible Phase 3 win could catalyze partnering across ophthalmology and rekindle interest in topical approaches for other back-of-the-eye indications. In a market where large ophthalmology players seek durable differentiation beyond dosing interval races, a proven delivery platform could attract M&A attention.
The June readout will be judged on effect size in BCVA and CST, steroid safety tolerability over 52 weeks, and practical adherence signals that translate to real-world use. If the data support both monotherapy in earlier disease and adjunct use in inadequate responders, Oculis could redefine how and where DME is treated. The next competitive frontier is clear: will a pharmacy-channel, non-invasive option earn a first-line foothold, or become an injection-sparing adjunct that still shifts share and economics across the DME ecosystem?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
